Wilson Therapeutics Transaction
Effective April 11, 2018, Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer. For transaction details and disclosures, please follow the link here.
Effective January 28, 2011, Alexion completed its acquisition of Taligen Therapeutics. The shareholders of Taligen Therapeutics have appointed Shareholder Representative Services as the shareholders' respresentative. If you have questions relating to your rights as a former Taligen shareholder, please contact email@example.com or 415-263-9018.